🚀 VC round data is live in beta, check it out!
Black Diamond Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Black Diamond Therapeutics and similar public comparables like Panion & Bf Biotech, Unicycive, Easywell Biomedicals, Tetratherix and more.
Black Diamond Therapeutics Overview
About Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Founded
2016
HQ
Employees
24
Website
Financials (LTM)
EV
$66M
Black Diamond Therapeutics Financials
Black Diamond Therapeutics reported last 12-month revenue of $51M and negative EBITDA of ($3M).
In the same LTM period, Black Diamond Therapeutics generated $51M in gross profit, ($3M) in EBITDA losses, and $4M in net income.
Revenue (LTM)
Black Diamond Therapeutics P&L
In the most recent fiscal year, Black Diamond Therapeutics reported revenue of $70M and EBITDA of $20M.
Black Diamond Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $51M | XXX | $70M | XXX | XXX | XXX |
| Gross Profit | $51M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($3M) | XXX | $20M | XXX | XXX | XXX |
| EBITDA Margin | (6%) | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | (6%) | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $4M | XXX | $22M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 32% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Black Diamond Therapeutics Stock Performance
Black Diamond Therapeutics has current market cap of $176M, and enterprise value of $66M.
Market Cap Evolution
Black Diamond Therapeutics' stock price is $3.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $66M | $176M | 0.0% | XXX | XXX | XXX | $0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBlack Diamond Therapeutics Valuation Multiples
Black Diamond Therapeutics trades at 1.3x EV/Revenue multiple, and (20.8x) EV/EBITDA.
EV / Revenue (LTM)
Black Diamond Therapeutics Financial Valuation Multiples
As of April 20, 2026, Black Diamond Therapeutics has market cap of $176M and EV of $66M.
Equity research analysts estimate Black Diamond Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Black Diamond Therapeutics has a P/E ratio of 48.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $176M | XXX | $176M | XXX | XXX | XXX |
| EV (current) | $66M | XXX | $66M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | (20.8x) | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBIT | (21.9x) | XXX | 3.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.3x | XXX | — | XXX | XXX | XXX |
| P/E | 48.3x | XXX | 7.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Black Diamond Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Black Diamond Therapeutics Margins & Growth Rates
Black Diamond Therapeutics' revenue in the last 12 month declined by (90%).
Black Diamond Therapeutics' revenue per employee in the last FY averaged $2.9M, while opex per employee averaged $2.1M for the same period.
Black Diamond Therapeutics' rule of 40 is (737%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Black Diamond Therapeutics' rule of X is (872%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Black Diamond Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (90%) | XXX | (90%) | XXX | XXX | XXX |
| EBITDA Margin | (6%) | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 1413% | XXX | (329%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (737%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (872%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 38% | XXX | 27% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 67% | XXX | 48% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 72% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Black Diamond Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Black Diamond Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Panion & Bf Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Unicycive | XXX | XXX | XXX | XXX | XXX | XXX |
| Easywell Biomedicals | XXX | XXX | XXX | XXX | XXX | XXX |
| Tetratherix | XXX | XXX | XXX | XXX | XXX | XXX |
| Replimune Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Black Diamond Therapeutics M&A Activity
Black Diamond Therapeutics acquired XXX companies to date.
Last acquisition by Black Diamond Therapeutics was on XXXXXXXX, XXXXX. Black Diamond Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Black Diamond Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBlack Diamond Therapeutics Investment Activity
Black Diamond Therapeutics invested in XXX companies to date.
Black Diamond Therapeutics made its latest investment on XXXXXXXX, XXXXX. Black Diamond Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Black Diamond Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Black Diamond Therapeutics
| When was Black Diamond Therapeutics founded? | Black Diamond Therapeutics was founded in 2016. |
| Where is Black Diamond Therapeutics headquartered? | Black Diamond Therapeutics is headquartered in United States. |
| How many employees does Black Diamond Therapeutics have? | As of today, Black Diamond Therapeutics has over 24 employees. |
| Who is the CEO of Black Diamond Therapeutics? | Black Diamond Therapeutics' CEO is Mark A. Velleca. |
| Is Black Diamond Therapeutics publicly listed? | Yes, Black Diamond Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Black Diamond Therapeutics? | Black Diamond Therapeutics trades under BDTX ticker. |
| When did Black Diamond Therapeutics go public? | Black Diamond Therapeutics went public in 2020. |
| Who are competitors of Black Diamond Therapeutics? | Black Diamond Therapeutics main competitors are Panion & Bf Biotech, Unicycive, Easywell Biomedicals, Tetratherix. |
| What is the current market cap of Black Diamond Therapeutics? | Black Diamond Therapeutics' current market cap is $176M. |
| What is the current revenue of Black Diamond Therapeutics? | Black Diamond Therapeutics' last 12 months revenue is $51M. |
| What is the current revenue growth of Black Diamond Therapeutics? | Black Diamond Therapeutics revenue growth (NTM/LTM) is (90%). |
| What is the current EV/Revenue multiple of Black Diamond Therapeutics? | Current revenue multiple of Black Diamond Therapeutics is 1.3x. |
| Is Black Diamond Therapeutics profitable? | No, Black Diamond Therapeutics is not profitable. |
| What is the current EBITDA of Black Diamond Therapeutics? | Black Diamond Therapeutics has negative EBITDA and is not profitable. |
| What is Black Diamond Therapeutics' EBITDA margin? | Black Diamond Therapeutics' last 12 months EBITDA margin is (6%). |
| What is the current EV/EBITDA multiple of Black Diamond Therapeutics? | Current EBITDA multiple of Black Diamond Therapeutics is (20.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.